Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity

Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity

Background The paucity of tumor-specific targets for chimeric antigen receptor (CAR) T-cell therapy of solid tumors necessitates careful preclinical evaluation of the therapeutic window for candidate antigens. Human epidermal growth factor receptor 2 (HER2) is an attractive candidate for CAR T-cell...

Full description

Bibliographic Details
Main Authors: Stanley R Riddell, Ekram A Gad, Sylvain Simon, Tamer Basel Shabaneh, Andrew R Stevens, Sylvia M Stull, Kristen R Shimp, Brandon W Seaton, Carla A Jaeger-Ruckstuhl, Amanda L Koehne, Jason P Price, James M Olson, Benjamin G Hoffstrom, David Jellyman
Format: Article
Language:English
Published: BMJ Publishing Group 2024-02-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/12/2/e008566.full

Internet

https://jitc.bmj.com/content/12/2/e008566.full

Similar Items